Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 Induction Therapy in Moderately to Severely Active Crohn's Disease
2014-003240-12Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in Crohn's disease (3 arms), sponsored by AbbVie Inc. Primary endpoint: Co-primary endpoints. Started Mar 2015; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-003240-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003240-12.